Abstract
The term placebo refers to any intervention with no therapeutic effect that is used as a control in randomized controlled trials (RCTs). Placebo can produce a beneficial effect that cannot be attributed to the properties of the intervention itself, as it is inactive, and must, therefore, be due to the patient’s belief about treatment. Respectively, adverse events (AEs) may occur when using a placebo intervention, a phenomenon that is called nocebo.
Nocebo has been studied and was found to be very prevalent in various neurological conditions and, in particular, in many brain disorders including headache, Parkinson’s disease, Alzheimer’s disease, depression, epilepsy, multiple sclerosis, and motor neuron disease. Pooled AE rates in the placebo groups (nocebo AE rates) vary from 25% in the symptomatic treatment for multiple sclerosis RCTs to almost 80% in motor neuron disease RCTs. Pooled dropout rates because of AEs in the placebo groups (nocebo dropout rates) vary from 2% in multiple sclerosis RCTs to almost 10% in Parkinson’s disease RCTs. Across all brain disorders, the nature of AEs reported in the placebo-treated subjects mirrors those reported by active drug-treated subjects, suggesting that awareness of drug side effect profiles might have influenced patient expectations and, thus, nocebo responses.
Unexplored areas, where nocebo should be studied further, include psychiatric disorders (i.e., schizophrenia and bipolar disorder), vascular disorders (i.e., acute ischemic stroke, vascular dementia), degenerative disorders (i.e., frontotemporal dementia, Lewy body dementia), and other systemic atrophies of the brain (i.e., hereditary ataxias).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–7.
Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–71.
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10.
Dimitriadis PA, Zis P. Nocebo effect in Meniere’s disease: a meta-analysis of placebo-controlled randomized controlled trials. Otol Neurootol. 2017;38(9):1370–5.
Dodd S, Schacht A, Kelin K, Dueñas H, Reed VA, Williams LJ, Quirk FH, Malhi GS, Berk M. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 2015;76(6):702–11.
Elsenbruch S, Schmid J, Bäsler M, Cesko E, Schedlowski M, Benson S. How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women. Neurogastroenterol Motil. 2012;24(10):914–e460.
Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron. 2008;59:195–206.
Goldenholz DM, Moss R, Scott J, Auh S, Theodore WH. Confusing placebo effect with natural history in epilepsy: a big data approach. Ann Neurol. 2015;78(3):329–36.
Häuser W, Bartram C, Bartram-Wunn E, Tölle T. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain. 2012;28(5):437–51.
Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-Methyl-4-Phenyl-1,2,3,6-Tetra-Hydropyridine primate model of Parkinsonism. J Neurosci. 2006;26:8101–14.
Hirsch RL, Johnson KP, Camenga DL. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings. Int J Neurosci. 1988;39(3–4):189–96.
La Mantia L, Eoli M, Salmaggi A, Milanese C. Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature. Ital J Neurol Sci. 1996;17(2):135–9.
Lidstone SC. Great expectations: the placebo effect in Parkinson’s disease. Handb Exp Pharmacol. 2014;225:139–47.
Manchikanti L, Giordano J, Fellows B, Hirsch JA. Placebo and nocebo in interventional pain management: a friend or a foe—or simply foes? Pain Physician. 2011;14(2):E157–75.
Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012;12(2):132–7.
Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31(5):550–61.
Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol. 2012;19(5):672–80.
Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014;215(1):82–6.
Nehama Y, Rabinowitz I, Baruch Y, Mandel A, Lurie I, Barak Y. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy. Int Clin Psychopharmacol. 2014;29(2):106–10.
Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16(7):816–28.
Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012;259(3):436–47.
Rutherford BR, Wall MM, Glass A, Stewart JW. The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry. 2014;75(10):1040–6.
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65(2):220–31.
Shafiq F, Mitsikostas DD, Zis P. Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2017;8:1–7.
Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology. 2017;88(23):2216–24.
Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis. Eur J Neurol. 2013;20(3):527–33.
The Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.
Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16(11):1277–83.
Vallance AK. A systematic review comparing the functional neuroanatomy of patients with depression who respond to placebo to those who recover spontaneously: is there a biological basis for the placebo effect in depression? J Affect Disord. 2007;98(1–2):177–85.
World Health Organization. International classification of diseases, 10th revision (ICD-10). Geneva: World Health Organization; 1992.
Zaccara G, Giovannelli F, Cincotta M, Loiacono G, Verrotti A. Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. J Neurol. 2015;262(3):501–15.
Zis P, Mitsikostas DD. Nocebo in Alzheimer’s disease; meta-analysis of placebo-controlled clinical trials. J Neurol Sci. 2015;355(1–2):94–100.
Zis P, Shafiq F, Mitsikostas DD. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials. Seizure. 2017;45:95–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zis, P. (2019). Placebos and Nocebos in Other Brain Disorders. In: Mitsikostas, D., Benedetti, F. (eds) Placebos and Nocebos in Headaches. Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-02976-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-02976-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02975-3
Online ISBN: 978-3-030-02976-0
eBook Packages: MedicineMedicine (R0)